FDA Issues Highest Risk Warning For Cheeseburger Recall
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A brand of cheeseburgers is being recalled due to undeclared allergens.
Sheehan Brothers Vending issued a voluntary recall for its Cheeseburgers, which were distributed across three states, due to undeclared sesame.
As a result, the Food and Drug Administration (FDA) has classified the recall as a Class I health risk, the most serious type of recall.
Why It Matters
According to the FDA, millions of people in the U.S. have food allergies or food sensitivities. Food sensitivities can range from mild reactions to potentially life-threatening symptoms. The agency recognizes nine major food allergens: milk, eggs, sesame, fish, tree nuts, crustacean shellfish, peanuts, wheat and soybeans.
File photo dated 09/07/14 of a generic stock photo of a pile of cheeseburgers and french fries.
File photo dated 09/07/14 of a generic stock photo of a pile of cheeseburgers and french fries.
Press Association/AP
What To Know
As well as the cheeseburgers, the company is also recalling its Spicy Chicken Sandwich, Italian Mini Subs, Pepperoni Pizza Sub, Chili Cheese Coney and BBQ Riblet with coleslaw due to undeclared sesame.
All the products have been issued a Class I health risk.
A Class I health risk, as defined by the FDA, is issued when there is a reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death. This designation signals that the product poses an immediate danger to public health and requires urgent attention from both consumers and health professionals.
The affected products were distributed in Indiana, Kentucky, and Ohio, specifically through Micro Markets and vending machines located throughout all of Ohio, northern Kentucky, and eastern Indiana. They were available for purchase between July 2 and July 8, 2025.
The issue was identified during a routine inspection conducted by the Ohio Department of Agriculture. While no illnesses have been reported in connection with the recalled items, individuals with a sesame allergy or severe sensitivity are at risk of experiencing a serious or potentially life-threatening allergic reaction if they consume the product.
All the affected products were wrapped in plastic.
What People Are Saying
The FDA, in an email to Newsweek in January: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service.
"The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall."
It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled."
What Happens Next
Consumers who have a sesame allergy or sensitivity are advised to dispose of the affected product immediately and contact Sheehan Brothers Vending to receive a replacement pack. Anyone experiencing signs or symptoms of a foodborne illness or allergic reaction should seek medical attention promptly.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 minutes ago
- Newsweek
Wearable Sensor Will Improve Bipolar Disorder Treatment
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A wearable sensor could make tracking medication levels much easier for people living with bipolar disorder, eliminating the need for blood draws and lab analyses. The first-of-its-kind device could vastly improve treatment, convenience and drug safety for millions of patients who take lithium—a type of mood stabilizer—for bipolar disorder. While lithium is highly effective, it must be administered precisely and needs regular monitoring. Too low a dose, and the treatment doesn't work—but too high a dose can be toxic to patients, with the potential to cause kidney and thyroid damage, or even death. In addition, the correct dose of lithium depends on the individual. In their study, the researchers from the University of Southern California (USC) argue that sweat is an easier alternative to blood for lithium tracking because it can both be collected noninvasively and reflect lithium concentrations in real time. Printed and flexible wearable sensor for lithium monitoring in sweat being stuck to skin. Printed and flexible wearable sensor for lithium monitoring in sweat being stuck to skin. Mohammad Shafiqul Islam, Khan Lab, USC Viterbi School of Engineering Bipolar disorder affects around 5.7 million adult Americans, or about 2.6 percent of the U.S. population aged 18 and older each year, according to the National Institute of Mental Health. The current method of laboratory-based blood draws for tracking can be time-consuming, inconvenient and painful. "While past approaches required collecting body fluids for lab testing or using multiple devices—such as stimulating sweat, applying a color-changing lithium sensor, and then photographing it to estimate levels—our wearable simplifies everything," USC electrical and computer engineer professor Yasser Khan told Newsweek. "It collects sweat and measures lithium levels in one fully integrated, non-invasive device." The newly designed wearable includes a skin-safe, electrical current-based system to induce sweat without requiring physical exertion. In just minutes, the device can collect the data and transmit it directly to a smartphone app, allowing people to track their lithium levels from home (or wherever they might be). This reduces the need for more invasive tracking, similarly to a glucose monitor reducing the need for people with diabetes to check their blood glucose levels with a finger prick test, though they work slightly differently. "Unlike continuous glucose monitors (CGMs) that rely on a needle under the skin, our wearable is sweat-based and sticks on the skin like a simple bandage. While CGMs don't require a sample collection step, our device needs to first stimulate sweat before measuring lithium levels, adding one step, but avoiding needles entirely," Khan explained. The wearable sensor to track lithium has been made possible by the innovative use of something called 'organic electrochemical transistors' (OECTs) specifically designed for lithium detection, according to the researchers. OECTs are electronic devices that respond to ionic signals in liquid, converting them into readable electronic data. Unlike conventional OECTs, the sensor developed at USC features a fully printed OECT using a new material formulation tailored to detect lithium ions specifically. "We developed the entire lithium monitoring system—from the OECT-based sensor patch and on-demand sweat induction to the readout electronics and smartphone app—using a simple, scalable and cost-effective fabrication process," said study author and doctoral student Mohammad Shafiqul Islam in a statement. "Our goal was to make lithium tracking as easy and comfortable for patients as checking a daily fitness tracker." This makes it the first OECT-based lithium sensor to be entirely printed, which is hoped to pave the way for affordable and scalable production. In partnership with psychiatrist Adam Frank at Keck School of Medicine, the device has already been tested by those of his patients taking lithium—gaining positive feedback. Sweat samples were collected using the wearable device and lithium measurements were successfully matched against values derived from bulky commercial sensors. "We conducted a pilot study with three patients, focusing primarily on showcasing the wearable's development. All participants appreciated the convenience of using a simple at-home device compared to frequent lab visits for blood draws," Khan told Newsweek. "The wearable measures lithium levels and displays the concentration on a smartphone, making it accessible to both patients and physicians. Over time, patients can better understand what works for them—for example, one participant noted that a concentration around 0.4 mM was effective. This kind of personalized insight is one of the key benefits of wearable technologies." The new device is hoped to improve safety by allowing for medication dose adjustments that avoid side effects and potential medication toxicity. Keen to keep the momentum going for those living with bipolar disorder, Khan said: "This is a market-ready technology that now needs to be translated from the lab into a consumer device. To reach widespread adoption, a larger clinical study involving hundreds of patients will be essential." The team plans to develop more advanced wearable systems powered by AI to automatically adjust lithium dosage and achieve optimal therapeutic benefits without causing lithium toxicity. Do you have a health story to share with Newsweek? Do you have a question about bipolar disorder? Let us know via health@ Reference Islam, M. S., Kunnel, B. P., Ferdoushi, M., Hassan, M. F., Cha, S., Cai, W., Frank, A., & Khan, Y. (2025). Wearable organic-electrochemical-transistor-based lithium sensor for precision mental health. Device.
Business Wire
an hour ago
- Business Wire
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor. Ateganosine is a first-in-class small molecule that compromises telomere structure and function in cancer cells, leading to rapid tumor cell elimination and specific immune memory. Through telomerase-mediated action, ateganosine reverses intrinsic or acquired resistance to immune checkpoint inhibitors (ICIs). 'FDA's Fast Track Designation recognizes ateganosine's potential as a new therapeutic paradigm in cancer treatment science. Ateganosine is the first and only anticancer treatment of its kind that we are aware of in clinical development,' stated MAIA Chairman and CEO Vlad Vitoc, M.D. 'If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. If approved, ateganosine would have a first-to-market competitive position within a $34 billion NSCLC treatment market with significant unmet medical need.' NSCLC represents one of the largest global oncology indications. The market was valued at $34.1B in 2024 and is projected to reach $68.8B by 2033 with a projected CAGR of 8.1%. 1 'This is an important milestone for MAIA's clinical development program. Ateganosine has demonstrated robust preclinical efficacy and superior clinical median overall survival compared to other FDA-approved treatments for NSCLC patients with prior disease progression on platinum-based chemotherapy and anti-PD-(L)1 antibody. Additionally, advanced NSCLC is a devastating disease that clearly meets the criteria for a serious condition with unmet medical need. Both are key criteria for the Fast Track designation,' said K. Robinson Lewis, Vice President, Head of Regulatory and Quality at MAIA. 'We intend to utilize the incentives of the Fast Track Program to expedite the development and review of ateganosine and bring patient access sooner.' The FDA Fast Track is a process designed to facilitate development and expedite the review of drugs for treating serious conditions and filling an unmet medical need, as in providing a therapy where none exists or which may be potentially better than available therapy. If relevant criteria are met during the Fast Track process, a drug will be eligible for FDA Accelerated Approval and Priority Review (FDA decision within six months). MAIA's most recent data from the pivotal Phase 2 THIO-101 clinical trial of ateganosine as of May 15, 2025 showed median overall survival (OS) of 17.8 months in a heavily pre-treated population. As of the data cut-off date, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101 Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
CNET
an hour ago
- CNET
Think Higher SPF Is Better? Experts Say 30–50 Is Where It's At
Staying hydrated and cool might be at the top of your list this summer, but don't forget about sunscreen. Protecting your skin from the sun's UV rays is essential—not just to prevent sunburn, but to lower your risk of skin cancer and early signs of aging. With so many SPF options lining store shelves, it's easy to feel overwhelmed. That's why we asked a dermatologist to break down exactly what SPF number you should be reaching for. What is SPF? SPF, or sun protection factor, describes the amount of solar energy needed to produce a sunburn on protected skin relative to unprotected skin, according to the US Food and Drug Administration. Logic would follow, then, that wearing a higher SPF would offer you better protection when you're out and about, basking in the sun's rays. Is a higher SPF better? Is higher SPF sunscreen more protective in a measurable way that actually matters? The tested difference between SPF 30 and SPF 50 is small, according to Dr. Steven Daveluy, board-certified dermatologist and program director at Wayne State University Department of Dermatology. There was a difference of 96.7% blocking versus 98% blocking, in one example he provided. Research on people wearing sunscreen out in "real life" has suggested higher SPFs are more protective, Daveluy said in an email. Combine this with the fact you're probably not wearing enough sunscreen -- studies have shown people apply only 25% to 50% of the amount that they should, Daveluy said -- and a higher SPF may come out reasonably more protective. "You should use about 1 ounce of sunscreen to cover your head, neck, arms and legs when wearing shorts and a T-shirt," Daveluy recommended, adding that people without hair should use a little more. "That means your 3-ounce tube of sunscreen is only three applications," Daveluy said. "Most people are not using that amount." What is the minimum SPF you need in a sunscreen? The American Academy of Dermatology Association recommends your sunscreen be SPF 30 or higher. It also recommends you look for sunscreen that has broad-spectrum protection (it protects against UVA and UVB rays) and make sure it's water-resistant. "If you follow the recommendations for the proper amount of sunscreen, then SPF 30 is great," Daveluy said. If you think you're skimping on the layers, though, a higher SPF could offer more benefit. He added that he generally recommends looking for at least SPF 50 or 60. Does skin tone matter when choosing an SPF? People with darker skin tones have more melanin, which does offer some protection from the sun's damaging rays. For this reason, skin cancer rates in people of color are lower than rates in white people, but the risk isn't zero. Research also suggests that people of color may be more likely to experience a missed or late diagnosis of skin cancer, making outcomes more dangerous. (It's also important to note that melanoma can have other causes besides exposure to sunlight or UV rays, and can show up in areas not typically exposed to sun.) "SPF 30 is the minimum for everyone," Daveluy said. He added that tinted sunscreens may be a better fit for darker skin tones, leaving less of a white cast. "If you have very fair skin, the higher [SPF] numbers may be a good idea, especially if you aren't using the proper amount, because you will see the consequences of underuse more easily," Daveluy said. Sunscreen red flags As long as you're wearing a minimum of SPF 30, applying it properly and also looking for products that are broad spectrum and water resistant, you've got the basics down. Daveluy added that for people with sensitive skin, finding a mineral sunscreen with "active ingredients of zinc and/or titanium" may be a good choice. Daveluy pointed out other measures of protecting yourself from the sun, including wearing a wide-brimmed hat, sun-protective clothing and hanging out in the shade when possible. But don't forget that sunscreen has a proven safety record going back for decades, he said. "The biggest red flags for sunscreen are any people or reports that try to tell you sunscreen isn't safe," Daveluy said.
